VRTX
VertexBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
CFTR franchise remains strong while new modalities (gene/gene-editing) deliver positive readouts or approvals, lifting revenue visibility and multiple expansion toward the high end of consensus.
Posture
Constructive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-06-03.
What can break
CFTR sales deceleration or payer pressure
Momentum
39
Value
62
Sentiment
70
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $530.16 · Bull $656.25 · Bear $330.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-14 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $541.48
Why
Momentum39 · Δ7d +0.8
Value62 · Δ7d +0.2
Sentiment70 · Δ7d +2.3
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
39
34% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+15.7
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.6
Sentiment
70
33% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
+7.9
Why this grade
Composite grade B. Momentum 38.7 / Value 61.9 / Sentiment 70.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$111.27B
Beta
0.31
Shares Out
253.72M
P/E (TTM)
31.5
P/S (TTM)
9.71
P/FCF (TTM)
34.12
Rev YoY
+11.0%
EPS YoY
+5.0%
Gross Margin
+86.3%
Op Margin
+34.1%
Net Debt
-$6B
Current Ratio
2.36
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology